Loading...
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer
Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin’s lymphoma). In July 2017, the US FDA granted accelerated approval of this agent for the treatment of metastatic...
Na minha lista:
| Udgivet i: | Future Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Future Medicine Ltd
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088272/ https://ncbi.nlm.nih.gov/pubmed/29473436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2017-0696 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|